Hand A, Pelin K, Halme M, Ekman A, Mattson M, Vallas M, Mattson K, Linnainmaa K, Husgafvel-Pursiainen K
Department of Industrial Hygiene and Toxicology, Institute of Occupational Health, Helsinki, Finland.
Anticancer Drugs. 1993 Jun;4(3):365-8.
Non-small cell lung cancers (NSCLC) are often resistant to chemotherapy. Cisplatin has shown the most activity against all the histological subtypes and is now used in most combined treatment programmes. Interferon (IFN)-alpha has been shown to potentiate cisplatin and other drugs experimentally and in clinical trials involving NSCLC. We are looking at the responses of different NSCLC cell lines to cisplatin (P), etoposide (VP-16) and IFN [recombinant human IFN-alpha 2c (IFN-alpha) and IFN-gamma 1b (IFN-gamma)], individually and in combination. We then compare the results with those from a clinical trial of etoposide and cisplatin with interferon in advanced NSCLC. We report here the results from the first of our cell lines, established from a large cell anaplastic carcinoma. We have confirmed earlier findings that NSCLC cell lines are not sensitive to either IFN-alpha or IFN-gamma alone. However a combination of IFN-alpha and IFN-gamma does reduce cell proliferation in our cell lines. This IFN combination potentiates the response of the cells to etoposide far more than to cisplatin. There is a trend towards greater activity when a combination of cisplatin and etoposide is used, compared with the activity of either drug alone. This effect is further increased by the interferon combination.
非小细胞肺癌（NSCLC）通常对化疗耐药。顺铂对所有组织学亚型均显示出最强的活性，目前已用于大多数联合治疗方案中。在涉及NSCLC的实验和临床试验中，α干扰素（IFN）已显示出可增强顺铂及其他药物的作用。我们正在研究不同NSCLC细胞系对顺铂（P）、依托泊苷（VP - 16）和干扰素[重组人α干扰素2c（IFN - α）和γ干扰素1b（IFN - γ）]单独及联合使用时的反应。然后，我们将结果与一项晚期NSCLC中依托泊苷、顺铂联合干扰素的临床试验结果进行比较。我们在此报告从一例大细胞间变性癌建立的首个细胞系的结果。我们证实了早期的发现，即NSCLC细胞系对单独的IFN - α或IFN - γ均不敏感。然而，IFN - α和IFN - γ的联合确实能减少我们细胞系中的细胞增殖。这种IFN联合增强细胞对依托泊苷反应的程度远大于对顺铂的反应。与单独使用任一药物相比，联合使用顺铂和依托泊苷时存在活性增强的趋势。干扰素联合使用可进一步增强这种效果。
